Q3 EPS Estimates for Traws Pharma Reduced by HC Wainwright

Traws Pharma, Inc. (NASDAQ:TRAW) – Equities research analysts at HC Wainwright decreased their Q3 2026 EPS estimates for Traws Pharma in a research note issued on Tuesday, August 18th. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($0.21) per share for the quarter, down from their prior forecast of ($0.08). HC Wainwright has a “Neutral” rating and a $1.00 price objective on the stock. The consensus estimate for Traws Pharma’s current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Traws Pharma’s Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($1.17) EPS, FY2027 earnings at ($0.59) EPS, FY2028 earnings at ($0.60) EPS, FY2029 earnings at ($0.34) EPS and FY2030 earnings at $0.02 EPS.

Other equities research analysts have also issued reports about the stock. Citigroup lowered shares of Traws Pharma to a “neutral” rating in a report on Monday, June 15th. Wall Street Zen upgraded Traws Pharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Weiss Ratings lowered Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. Finally, LADENBURG THALM/SH SH cut Traws Pharma from a “buy” rating to a “neutral” rating in a research note on Monday, June 15th. Four investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and a consensus target price of $1.00.

Traws Pharma Stock Performance

TRAW stock opened at $0.54 on Thursday. The business’s fifty day moving average price is $0.68 and its 200 day moving average price is $1.32. Traws Pharma has a 12-month low of $0.43 and a 12-month high of $3.27. The company has a market capitalization of $8.30 million, a PE ratio of -0.31 and a beta of 1.57.

Traws Pharma (NASDAQ:TRAW) last issued its quarterly earnings data on Friday, August 14th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.18.

Hedge Funds Weigh In On Traws Pharma

Large investors have recently bought and sold shares of the stock. Adage Capital Partners GP L.L.C. increased its position in shares of Traws Pharma by 121.2% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock worth $825,000 after purchasing an additional 400,000 shares in the last quarter. Squadron Capital Management LLC purchased a new position in Traws Pharma during the 4th quarter worth approximately $806,000. Ikarian Capital LLC grew its stake in Traws Pharma by 2,280.0% during the 4th quarter. Ikarian Capital LLC now owns 678,142 shares of the company’s stock worth $766,000 after buying an additional 649,649 shares during the last quarter. Boothbay Fund Management LLC acquired a new position in Traws Pharma during the fourth quarter worth approximately $220,000. Finally, ADAR1 Capital Management LLC purchased a new stake in Traws Pharma in the fourth quarter valued at approximately $175,000. Institutional investors and hedge funds own 7.95% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.